MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
Virios Therapeutics, LLC Book Value 2011-2026 | VIRI
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Virios Therapeutics, LLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.9 M | 64.3 M | 3.81 M | 7.33 M | 14.5 M | 29.9 M | -4.94 M | -1.26 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 74.9 M | -4.94 M | 23.6 M |
Quarterly Book Value Virios Therapeutics, LLC
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.4 M | 82.5 M | 82.7 M | 64.3 M | 949 K | 3.14 M | - | 3.81 M | 4.76 M | 4.69 M | 5.97 M | 7.33 M | 9.22 M | 7.14 M | 10.7 M | 14.5 M | 18.9 M | 22.9 M | 27.1 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82.7 M | 949 K | 25.8 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Ascendis Pharma A/S
ASND
|
-163 M | $ 229.25 | 0.44 % | $ 5 B |  Danmark |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
AbbVie
ABBV
|
134 B | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
227 M | $ 3.33 | -2.06 % | $ 99 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
225 M | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
225 M | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
90.6 B | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
429 M | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aurinia Pharmaceuticals
AUPH
|
581 M | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.68 | 1.52 % | $ 16.8 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B | Britain |
 |
Burford Capital Limited
BUR
|
1.66 B | $ 4.14 | -2.59 % | $ 683 M | Britain |
 |
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
275 M | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-476 M | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Axcella Health
AXLA
|
4.16 M | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 412.81 | -2.54 % | $ 31.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 318.85 | -3.01 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |